Hims & Hers obtains YourBio's microsampling tech, which the firm said will speed its efforts to improve blood collection, including outside traditional clinical settings.

Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.

The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.

Last week, readers were most interested in a story about FDA's plan to reclassify some tests that now require PMAs to require only 510(k) clearance.

The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.

NEW YORK – The US Food and Drug Administration on Tuesday released a proposal to reclassify companion diagnostic assays from Class III medical devices to Class II devices. In its proposal in the ...

The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.

The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.